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Recent studies of two newcomers to the TNF cytokine
family have revealed an unsuspected link between autoim-
munity and cancer. In this issue, Rennert et. al. (1) define
the specific receptors for the orphan ligand known as
APRIL (a proliferation-inducing ligand), which was previ-
ously recognized for its growth stimulating activity for tu-
mors of lymphoid, colon, and thyroid origin (2). APRIL
binds cell surface receptors B cell maturation antigen
(BCMA) and transmembrane activator and CAML interac-
tor (TACI) (see also reference 3); a soluble decoy form of
BCMA that antagonizes APRIL’s activity inhibits the
growth of tumors that naturally overexpress APRIL. What
makes this observation biologically intriguing is that the
two receptors, BCMA and TACI, were just very recently
recognized as receptors for another TNF family member,
BAFF, a B lymphocyte activating factor. BAFF is impli-
cated as a key cytokine sustaining B cell survival and may
play a significant role in lupus-like autoimmune nephritis
observed in NZB/WF1 mice. The definition of BAFF and
APRIL cytokine systems establishes a connection between
autoimmunity and cancer that is poised for detailed explo-
ration.
 
Ligands related to TNF are type 2 (NH
 
2
 
 terminus inside
the cell) single transmembrane proteins that assemble in
their biologically active form as trimers. In either mem-
brane-anchored or secreted states, the trimeric ligands bind
and aggregate their specific cell surface receptors, activating
cell death or survival signals (4, 5). The amino acid se-
quence homology that defines the TNF family is limited to
the receptor-binding domain, which between APRIL and
BAFF (also known as BlyS, THANK, TALL, zTNF4; ref-
erences 6–9) is only 33% identical, an insufficient clue as to
their closer functional ties. Both ligands are similarly pro-
cessed by a furin-like proteinase that releases biologically
active soluble trimers, which circulates in serum and thus
may act systemically (10).
 
A significant breakthrough came with recent reports by
Gross et al. (9) and others (11–15) that the biological func-
tions of BAFF are signaled through two orphans in the
TNF receptor family, TACI and BCMA. Both are type 1
single transmembrane glycoproteins with a cysteine-rich
extracellular (ecto) domain that identifies a distant relation-
ship to the other cognates in the TNF receptor family (16).
BCMA and TACI bind APRIL and BAFF with relatively
high affinity (low nanomolar range), as measured by surro-
gate receptors formed with the receptor’s ectodomain fused
with the Fc region of IgG1, creating soluble dimeric fusion
proteins (1, 3). Some selectivity in binding is observed,
with TACI–BAFF and BCMA–APRIL being favored part-
ners (Fig. 1). Neither BAFF nor APRIL bind any of the
other known members of the TNF receptor family, includ-
ing herpes virus entry mediator (HVEM) and Fas, which is
in contrast to a previous report (17). The shared pairing of
APRIL and BAFF and their receptors is now emerging as
the rule rather than the exception in the TNF superfamily
 
(e.g., TNF/LT
 
a
 
, LT
 
a
 
b
 
/LIGHT), yet each cytokine pair
identified so far has a unique physiologic purpose. TACI
was originally identified as a receptor protein that activates
nuclear factor of activated T cells, a transcription factor in-
volved in T cell activation (18), but also stimulates nuclear
factor (NF)-
 
k
 
B/Rel and activator protein (AP)-1 families
of transcription factors (3), which orchestrate gene expres-
sion involved in B cell development, inflammation, and
cellular stress responses. By contrast, BCMA was identified
in a T cell lymphoma as a chromosomal translocation at t(4;
16) at the IL-2 locus (16). The cytoplasmic tails of TACI
and BCMA are nonconserved and contain neither a death
domain, which is the characteristic signaling domain in Fas,
TNFR1, and TRAIL receptors, nor a recognizable TRAF
binding motif that is present in LT
 
b
 
R, CD40, CD30, and
several other family members. Most if not all of the mem-
bers of the TNF receptor family activate NF-
 
k
 
B and AP-1
via TRAF family of adaptors, and TACI and BCMA are
not exceptions (12–15). TACI and BCMA are reported to
bind a distinct set of TRAFs, BCMA recruits TRAF1, -2,
and -3, and TACI interacts with TRAF2, -5, and 6, which
suggests that they may activate different pathways. How-
ever, a clear link between a particular TRAF adaptor and a
phenotype associated with a given receptor is lacking at this
time. Nonetheless, the physiologic activities initiated by
BCMA and TACI are emerging.
 
BCMA is tightly restricted in its expression to CD19
 
1
 
resting mature B cells, as is TACI (although some T cells
express TACI), which provided a firm basis for the biolog-
ical functions induced by BAFF (19). Mice that express
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BAFF as a transgene (8, 9, 20) have enlarged spleens and
lymph nodes that are engorged with antigen-responsive
mature B cells (B220
 
1
 
, surface IgM
 
1
 
, IgD
 
1
 
). The B cells in
BAFF-transgenic mice express an activated phenotype with
increased expression of MHC class II antigen presenting
molecules and the antiapoptotic gene Bcl2. By contrast, the
T cell compartment was modestly decreased, although the
percentage of effector T cells appeared elevated in some
mice. A key observation that established a direct connec-
tion to lupus was the presence of antibodies to DNA, a
hallmark of lupus, as well as other autoimmune Igs, such as
rheumatoid factors in BAFF-transgenic mice (20). As
BAFF-transgenic animals age, they display overt signs of lu-
pus nephritis, with protein spilling to the urine, enlarged
glomeruli containing fibrin deposits, and cellular infiltrates
that precede frank loss of kidney function. Gross et al. (9)
showed that NZB/WF1 mice, which are genetically prone
to autoimmune nephritis, have BAFF in their sera that cor-
responds to disease progression. Using a TACI decoy re-
ceptor injected into the nephritis prone mice, Gross et al.
then showed a reduction in the level of activated B cells
with alleviation of nephritis.
The effect of BAFF on B lymphocytes appears to be dis-
tinct from that of CD40–CD40L system, already well
known for its role in B cell biology (21). CD40L is ex-
pressed by activated CD4
 
1
 
 T cells and plays a critical role as
a survival factor of activated B cells and acts as a cofactor for
B cell effector function. On the other hand, BAFF is consti-
tutively produced by macrophages and possible dendritic
cells and activated T cells. Batten et al. (22) show that BAFF
allows survival and differentiation of a subset of immature B
lymphocytes found in the spleen, the transitional type 2
cell, which are subject to negative selection for removal of
autoreactive clones. BAFF overexpression may break toler-
ance to self by promoting survival of immature B cells.
Thus, BAFF is important in B cell maturation and homeo-
stasis, whereas CD40L is a cofactor for B cell activation.
APRIL, in contrast to many other TNF-related ligands,
revealed itself as a factor that promotes survival of tumor
cells in tissue culture and when human tumors are trans-
planted into immune-deficient mice (2). Indeed, the ex-
pression of APRIL is nearly undetectable in normal tissue
but dramatically elevated in tumor tissue. Addition of re-
combinant APRIL or transfection of tumor lines with
APRIL provided a significant growth advantage to lym-
phoid and nonlymphoid cells. This suggests that APRIL
expression may be a consequence of the stress of malignant
transformation. However, adenocarcinoma tumor cells lack
any detectable expression of BCMA or TACI, implicating
the existence of yet another receptor specific for APRIL.
NIH3T3 fibroblastic tumor cells bind recombinant APRIL
but not BAFF, demonstrating the existence of an as yet un-
characterized APRIL receptor. This result suggests that this
other receptor may signal specific effects of APRIL in non-
lymphoid cells. Having shown that APRIL binds TACI
and BCMA, Rennert et al. (1) take it a step further and
demonstrate, again with the versatile soluble BCMA decoy
receptor, that the growth of human tumors HT29 colon
carcinoma and A549 lung carcinoma is suppressed when
transplanted into immune-deficient mice.
The definition of the APRIL/BAFF cytokine systems
provides a major advance in understanding molecular
mechanisms of B lymphocyte and tumor cell survival path-
ways. The results raise additional but addressable questions
that could provide a clearer picture of fundamental pro-
cesses in autoimmunity and cancer, as well as new thera-
peutic targets. Among several questions is whether APRIL-
like BAFF plays a significant role in B cell biology and
which receptor, TACI or BCMA, is involved in B cell ho-
meostasis and autoimmunity. This question has a practical
implication in whether a decoy receptor that targets both
cytokines or an antibody specific for a single ligand should
be selected as the appropriate antagonist. The favored part-
nering of APRIL with BCMA and BAFF with TACI sug-
gests that their roles may diverge. BAFF stimulates B cells
when the cells are coactivated via their antigen receptors
and induces expression of Bcl2, a critical antiapoptotic gene
initially described for its oncogenic effect in B cell transfor-
mation. These findings indicate that BAFF acts as a survival
factor rather than as a true growth factor. APRIL may like-
wise provide protective signals that help tumor cells survive
their hostile microenvironment by arresting apoptosis.
APRIL could provide these signals in an autocrine fashion,
acting via its specific receptor expressed on the tumor cells.
In a more insidious fashion, APRIL could also act in a
Figure 1. The BAFF/APRIL cytokine systems. This schematic shows
the two TNF-related cytokines, BAFF and APRIL, in their membrane-
anchored states binding with their cognate receptors, TACI and BCMA,
expressed on B lymphocytes, and a candidate APRIL-specific receptor
expressed on epithelial cells. Arrows indicate ligand–receptor binding in-
teractions; and bold arrows indicate the preferred binding partners. TACI
and BCMA activate signal transduction pathways that enhance cell sur-
vival. Tumor cells also express APRIL and thus may be able to directly
activate B cells via TACI or BCMA. 
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paracrine mode, stimulating B cells in the microenviron-
ment of the malignant cell. In this latter scenario, epithelial
cell transformation with concurrent expression of APRIL
could provide the necessary signals, in the presence of a
continuous antigenic burden (e.g., in the intestinal mu-
cosa), that breaks immune tolerance leading to autoanti-
body production. Autoantibody, in turn, could participate
in generation of an inflammatory milieu sufficient to sustain
continued expression of APRIL. Such a scenario could un-
derlie the increased incidence of tumors in organ-specific
and systemic autoimmune diseases. Whether BAFF or
APRIL play key roles in human lupus erythematosus or tu-
morigenesis, as suspected from the animal models, remains
to be established but is not far away from being experimen-
tally tested. More importantly, direct intervention targeted
at BAFF, APRIL, or both is readily accomplished with the
soluble decoys of TACI or BCMA and, presumably, the
forthcoming APRIL receptor. This could be the pharma-
ceutical version of the “two for the price of one.”
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